Good morning :)
Place Order
Add to Watchlist

Shilpa Medicare Ltd

SHILPAMED

Shilpa Medicare Ltd

SHILPAMED
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,649 cr, stock is ranked 640
High RiskStock is 3.55x as volatile as Nifty
680.002.74% (+18.15)
680.002.74% (+18.15)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,649 cr, stock is ranked 640
High RiskStock is 3.55x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,649 cr, stock is ranked 640
High RiskStock is 3.55x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
75.323.69—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
48.676.190.55%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation.

Investor Presentation

View older 

Feb 10, 2025

PDF
View Older Presentations
PE Ratio
43.75
1Y Return
13.24%
Buy Reco %
85.29
PE Ratio
28.85
1Y Return
0.99%
Buy Reco %
72.73
PE Ratio
62.82
1Y Return
17.26%
Buy Reco %
70.37
PE Ratio
53.95
1Y Return
14.92%
Buy Reco %
80.00
PE Ratio
18.28
1Y Return
3.43%
Buy Reco %
43.75
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 8.18%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.36% to 0.31%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -22.26%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue724.00798.83810.50786.96924.85992.111,168.761,067.511,165.901,271.85
Raw Materialssubtract374.23418.27313.83256.81293.78329.56390.24401.45442.33941.00
Power & Fuel Costsubtract24.4426.3028.8633.5738.7640.2552.4356.7952.41
Employee Costsubtract91.45127.87149.35176.40196.59235.31264.49286.39281.49
Selling & Administrative Expensessubtract49.3348.3959.0254.50115.69104.32158.09116.5597.93
Operating & Other expensessubtract26.96-2.2682.7984.2643.6511.7780.2890.4637.72
Depreciation/Amortizationsubtract28.6330.6437.2242.0643.7853.9879.8095.50107.87110.83
Interest & Other Itemssubtract6.863.132.663.684.5621.8741.1758.6591.8185.24
Taxes & Other Itemssubtract18.3238.9231.5223.4231.9147.2741.60-5.7522.4746.49
EPS13.4613.6813.0213.7719.1518.137.21-3.753.6710.17
DPS0.600.600.701.001.101.101.100.000.000.00
Payout ratio0.040.040.050.070.060.060.150.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Feb 10PDF
Oct 29PDF
FY 2023

Annual report

PDF

Investor Presentation

May 25PDF
Feb 15PDF
Nov 13PDF
Aug 12PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 10PDF
Feb 10PDF
Nov 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Shilpa Medicare Ltd208.653.69—
Sun Pharmaceutical Industries Ltd43.756.240.77%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd62.8215.180.91%

Price Comparison

Compare SHILPAMED with any stock or ETF
Compare SHILPAMED with any stock or ETF
SHILPAMED
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.23%4.89%3.37%9.90%37.60%

Apr 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

Dec '23MarAprJunSepDec '248.52%5.69%9.68%9.08%9.58%9.90%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Shilpa Medicare Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.2770%0.89%-0.18%110/203 (-2)
1.1327%0.54%-0.11%57/88 (-1)
1.0561%1.39%-0.41%22/55 (-7)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2022

Final
Final | Div/Share: ₹1.10

Dividend/Share

₹1.10

Ex DateEx Date

Sep 19, 2022

Cash Dividend

Ex DateEx DateSep 20, 2021

Final
Final | Div/Share: ₹1.10

Dividend/Share

₹1.10

Ex DateEx Date

Sep 20, 2021

Cash Dividend

Ex DateEx DateMar 16, 2020

Interim
Interim | Div/Share: ₹1.10

Dividend/Share

₹1.10

Ex DateEx Date

Mar 16, 2020

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 12, 2019

Cash Dividend

Ex DateEx DateMar 1, 2018

Interim
Interim | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Mar 1, 2018

News & Opinions
Corporate
Shilpa Medicare receives CDSCO approval for its IND - Nor Ursodeoxycholic Acid Tablets 500 mg

Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing authorization for this IND for the treatment of non-alcoholic fatty liver disease (NAFLD). Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 - Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled 'A phase - III, Randomized, Double- Blind, placebo controlled, multicenter, Parallel group study' to evaluate the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients suffering from Non-alcoholic Fatty Liver Disease to the SEC. This trial was a multicentric, placebo controlled double blinded study conducted on total 165 Non-alcoholic fatty liver disease (NAFLD) patients across India - a significant statistically powered number of patients leading to better reliability of data and results. No serious adverse events were reported in this phase 3 study and the treatment was well tolerated at the dose of 1500 mg per day for the duration of 24 weeks. The Phase 3 trial has met all the primary efficacy endpoints set in the clinical trial protocol, demonstrating a significant improvement in fatty liver stage. In this study 165 participants were randomised to assess and compare the efficacy and safety of nor UDCA 1500 mg against placebo. The data analysis has confirmed that liver fibrosis stage was reversed in significant majority of participants (83.3%) and stabilised in rest, within 24 weeks of nor UDCA treatment. (Primary endpoint) The elevated alanine transaminase (ALT) levels of NAFLD were normalized in significant proportion of participants (~90%) within 12 weeks of study (Primary endpoint). These results indicate that Nor UDCA could become a new standard of care with significant improvements in restoring liver function in NAFLD patients. This IND is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD).      Powered by Capital Market - Live

10 hours agoCapital Market - Live
Earnings
Shilpa Medicare consolidated net profit rises 593.89% in the December 2024 quarter

Net profit of Shilpa Medicare rose 593.89% to Rs 31.78 crore in the quarter ended December 2024 as against Rs 4.58 crore during the previous quarter ended December 2023. Sales rose 11.35% to Rs 319.32 crore in the quarter ended December 2024 as against Rs 286.76 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales319.32286.76 11 OPM %25.2722.72 - PBDT70.4240.87 72 PBT41.6114.17 194 NP31.784.58 594 Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Shilpa Medicare Q3 PAT zooms 594% YoY to Rs 32 crore

Revenue from operations was at Rs 319.32 crore, up 11.35% year on year, driven by healthy performance in fast-growing verticals, viz. (finished dosage forms) FDF and biologics. EBITDA jumped 20% to Rs 82 crore in Q3 FY25 from Rs 68 crore registered in Q3 FY24. EBITDA margin improved to 26% in Q3 FY25 from 24% in Q3 FY24. Total expenses were up by 2.09% year on year to Rs 279.18 crore in the quarter ended 31 December 2024. The cost of materials consumed stood at Rs 89.98 crore (down 14.95% YoY), while employee benefits expense was at Rs 73.49 crore (up 6.44% YoY). On a nine-month basis, the company's consolidated net profit zoomed 765.40% to Rs 63.78 crore in 9M FY25 as compared to Rs 7.37 crore recorded in 9M FY24. Revenue from operations jumped 11.13% YoY to Rs 955.62 crore in 9M FY25. Vishnukant Bhutada, managing director of Shilpa Medicare, said, 'Our 3QFY25 performance reflects robust growth in profitability driven by an improved business mix. The quarter witnessed healthy YoY growth in our key verticals of FDF on the biologics front, we have initiated Ph3 trials for Aflibercept; and we have initiated commercial launch quantities for OLC, a US CDMO opportunity. I am also highly optimistic on receiving approval for our NCE'NorUDCA'in this financial year. With positive traction on our new product launches in the coming quarters, I am confident of delivering strong revenue growth in each business vertical. Going forward, our focus remains on scaling up API business, launching approved NDAs in regulated markets, and getting timely approvals on filed products. We continue to invest in future pipelines as well as focus on resolutions on the regulatory front. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. Shares of Shilpa Medicare tanked 5.96% to currently trade at Rs 686.95 on the BSE.Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Shilpa Medicare to convene board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Shilpa Medicare gets European authority nod for Tadalafil drug

The approved drug is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. The total Europe market for oral Tadalafil formulations is estimated at about $400 million. The drug maker stated that it becomes the first company in the world to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing film formulation. This approval is a hybrid application and Shilpa's product is bioequivalent to the reference product. The approval has been granted for the company's finished dosage form manufacturing facility, Unit VI, located in Dabaspet, Bengaluru, Karnataka. Currently approved by the MHRA UK, this marks the second approval for a prescription oral mouth-dissolving film product in the European/UK regulated markets from this facility. It is involved in the manufacturing, packaging, labeling, and testing of finished dosage forms, including oral dispersible/dissolving films and transdermal patches. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip tumbled 3.85% to currently trade at Rs 778.35 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Shilpa Medicare gets GMP approval for Hyderabad facilities

Both units of Shilpa Medicare's (Unit IV and Unit VII) have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia. This approval will open up significant business opportunities in these countries. Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms, and other testing activities. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.33% to currently trade at Rs 767.30 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Shilpa Medicare's Unit IV and Unit VII secures Eurasia GMP approval

Shilpa Medicare, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024. Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia. This approval will open up significant business opportunities in these countries. Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Shilpa Medicare gets GMP certification for Hyderabad Facility

The inspection was conducted from 24 September 2024 to 26 September 2024. On conclusion of the inspection the company has received the Good Manufacturing Practice (GMP) Certification. Unit VII of Shilpa Medicare houses an Analytical Services Division (QC) and a Bio-Analytical Department, both of which are approved by the USFDA. Notably, the Bio-Analytical Laboratory is already approved by EMA, Europe. This inspection was the first Europe inspection for the QC laboratory of Unit VII. This Laboratory is involved in testing drug substances, raw materials, packing materials and finished products. It is also engaged in other analytical activities like analytical method validations, method transfers and other miscellaneous analytical studies. The laboratory has been testing samples for final release into US, EU and other markets. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.03% to Rs 828.75 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Shilpa Medicare JV gets USFDA approval for IMKELDI drug

Oncosol is 50:50 joint venture between Liqmeds Lifecare, a Zydus Group company, and Koana Healthcare, a Shilpa Medicare Group company. IMKELDI is an advanced liquid formulation of imatinib designed for dosing accuracy. It helps slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), and gastrointestinal tumors (GIST). 'In 2024, an estimated 9,280 people will be diagnosed with CML, over 10,000 with MDS/MPD, and up to 6,000 with GIST in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue, underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system,' the company stated in exchange filing. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip rose 0.42% to Rs 892.50 on the BSE.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Shilpa Medicare gets nod for Phase III clinical trials of Human Albumin

Albumin is in high demand for various medical treatments, including restoring blood volume and replacing lost fluids during accidents, serious burn injuries, fatal erythroblastosis, hypoproteinemia, and surgeries. However, the supply of human serum albumin is limited due to the reliance on whole blood or donated human plasma. Shilpa's Recombinant Human Albumin 20% (rHA), derived from yeast, offers a highly purified, structurally and functionally equivalent alternative to human serum albumin. The company has successfully completed its Phase I clinical trials on 7 August 2024. With today's announcement, the company confirms that the SEC has accepted the trial results and approved the progression to Phase III trials for rHA 20%. The Phase III trials will be conducted according to the protocol approved by the SEC. Shilpa is the first company in India to receive the approval for conducting Phase III clinical trials. This approval clears regulatory strategy for India and various emerging markets that accept Indian studies and is an important step towards providing a reliable and safe alternative to human serum albumin, addressing the global demand and supply challenges. Raichur-based Shilpa Medicare is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.66% to Rs 889.25 on the BSE. Powered by Capital Market - Live

2 months agoCapital Market - Live